Peers: AXSM RYTM INCY KYMR BMRN CRNX NBIX VKTX KRYS MDGL

| Held by: IWM IWO FESM VTWO PSIL IWC GWX VTWG GSSC AVSC

Index	RUT
Market Cap	586.52M
Enterprise Value	369.60M
Income	-17.75M
Sales	0.00M
Book/sh	21.99
Cash/sh	22.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	25
IPO	Mar 22, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.70
P/C	2.70
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	121.97
Current Ratio	121.97
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-2.08
EPS next Y	-6.24
EPS next Q	-1.06
EPS this Y	-95.10%
EPS next Y	-145.68%
EPS next 5Y	-
EPS past 3/5Y	35.51% -35.46%
Sales past 3/5Y	- -
EPS Y/Y TTM	-120.28%
Sales Y/Y TTM	-
EPS Q/Q	67.03%
Sales Q/Q	-
Earnings	Aug 17 BMO
EPS/Sales Surpr.	85.85% -

Insider Own	23.39%
Insider Trans	-4.52%
Inst Own	83.47%
Inst Trans	2.90%
ROA	-13.80%
ROE	-13.93%
ROIC	-8.18%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-12.06%
SMA50	-18.58%
SMA200	-23.58%
Trades

Shs Outstand	9.86M
Shs Float	7.56M
Short Float	11.82%
Short Ratio	4.74
Short Interest	0.89M
52W High	123.75 -51.95%
52W Low	48.90 21.60%
Volatility	4.39% 4.44%
ATR (14)	3.33
RSI (14)	30.74
Beta	-5.21
Rel Volume	0.00
Avg Volume	188.54K
Volume	0

Perf Week	-6.18%
Perf Month	-24.31%
Perf Quarter	-6.35%
Perf Half Y	-16.98%
Perf YTD	-23.81%
Perf Year	11.60%
Perf 3Y	3278.41%
Perf 5Y	99.50%
Perf 10Y	-
Recom	1.14
Target Price	149.56
Prev Close	59.46
Price	59.46
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-13-26	Initiated	Jefferies	Buy	$145
Sep-08-25	Initiated	BTIG Research	Buy	$72
May-13-25	Initiated	TD Cowen	Buy
May-07-25	Initiated	Chardan Capital Markets	Buy	$80
Jan-23-25	Initiated	Piper Sandler	Overweight	$93
Jan-10-25	Initiated	H.C. Wainwright	Buy	$85
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Nov-26-24	Initiated	Robert W. Baird	Outperform	$75

Sep-04-26 04:30PM	Bright Minds Biosciences to Present at Upcoming Conferences (GlobeNewswire)
Aug-28-26 12:31PM	What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now? (Quartz)
May-26-26 07:18PM	Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
Mar-06-26 10:15AM	Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results (TipRanks)
Feb-25-26 04:30PM	Bright Minds Biosciences to Present at Upcoming Conferences (GlobeNewswire) -5.00%
09:31PM	Loading…
Feb-18-26 09:31PM	Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials (Insider Monkey) +7.20%
Feb-17-26 10:09AM	Canadian Securities Exchange Reports January 2026 Performance Figures (TMX Newsfile) +7.72%
Jan-09-26 11:56AM	Bright Minds Biosciences Announces Closing of US$175 Million Public Offering (GlobeNewswire)
Jan-07-26 09:33PM	Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock (GlobeNewswire) -6.22%
Jan-06-26 04:00PM	Bright Minds Biosciences Announces Launch of US$100 Million Public Offering (GlobeNewswire) +16.50%
07:16AM	Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) (GlobeNewswire)
Jan-05-26 04:30PM	Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 (GlobeNewswire)
Nov-26-25 08:55AM	Recent Price Trend in Bright Minds Biosciences Inc. (DRUG) is Your Friend, Here's Why (Zacks)
Nov-25-25 04:30PM	Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting (GlobeNewswire) +8.37%
09:55AM	Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet (Zacks)
05:29PM	Loading…
Nov-17-25 05:29PM	Why Bright Minds Biosciences Stock Topped the Market on Monday (Motley Fool)
06:50AM	Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS) (GlobeNewswire)
Nov-06-25 06:30AM	Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH (GlobeNewswire) +7.55%
Oct-30-25 06:30PM	Bright Minds Biosciences to Present at Upcoming Conferences (GlobeNewswire)
Oct-15-25 08:50AM	Bright Minds Biosciences Inc. (DRUG) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Sep-18-25 09:55AM	Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade (Zacks) +12.23%
Sep-07-25 05:29PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Sep-04-25 08:30AM	Bright Minds Biosciences Announces BMB-201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model (GlobeNewswire)
Sep-02-25 09:55AM	Does Bright Minds Biosciences Inc. (DRUG) Have the Potential to Rally 114.07% as Wall Street Analysts Expect? (Zacks)
03:50AM	Bright Minds Biosciences Inc. (DRUG) Advances Phase 2 Trial for Drug-Resistant Epilepsy (Insider Monkey)
Aug-25-25 08:00AM	Bright Minds Biosciences to Present at Upcoming Conferences (GlobeNewswire) -5.14%
May-28-25 08:00AM	Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 08:00AM	Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025 (GlobeNewswire)
May-13-25 08:30AM	Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101 (GlobeNewswire)
May-11-25 03:33PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
11:11AM	Loading…
May-09-25 11:11AM	Psychedelic: Compass, GH Research, MindMed report quarterly earnings (TipRanks)
Apr-28-25 08:00AM	Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study (GlobeNewswire)
Apr-16-25 12:09PM	Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025 (Seeking Alpha)
Mar-04-25 08:00AM	Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research (GlobeNewswire) -7.70%
Feb-24-25 06:50AM	Bright Minds Biosciences to Participate at Three Healthcare Conferences in March (GlobeNewswire)
Jan-07-25 06:50AM	Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
Nov-21-24 09:00AM	Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting (GlobeNewswire)
Nov-06-24 06:30AM	Bright Minds Biosciences Secures $35 Million Investment (TipRanks)
Nov-04-24 02:41PM	Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement (GlobeNewswire) +5.00%
Oct-21-24 08:30AM	Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data (GlobeNewswire)
Oct-18-24 06:50AM	Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement (GlobeNewswire) +117.56%
Oct-16-24 10:45AM	Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models (GlobeNewswire) -25.18%
09:20AM	Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA Technology (GlobeNewswire)
05:57AM	Biotech stock tumbles after unexplained 1,446% gain (MarketWatch)
Oct-15-24 09:09PM	Bright Minds is Unaware of Any Material Changes (Newsfile) +1,445.78%
Oct-03-24 09:00AM	Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events (GlobeNewswire)
Sep-19-24 10:00AM	Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th (GlobeNewswire)
Sep-12-24 08:00AM	Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy (PR Newswire)
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
May-20-24 11:53AM	DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q2 2024 (InvestorPlace)
Dec-06-23 05:08PM	Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management (PR Newswire) +5.53%
Aug-08-23 06:50AM	Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101 (GlobeNewswire) +29.50%
Jul-20-23 06:50AM	Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101 (GlobeNewswire) -16.38%
Jul-11-23 06:50AM	Bright Minds Announces Effective Date of Share Consolidation (GlobeNewswire)
Jun-22-23 06:50AM	Bright Minds Announces Proposed Share Consolidation (GlobeNewswire) +5.33%
Apr-19-23 06:50AM	Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202 (GlobeNewswire) +26.08%
Apr-10-23 06:50AM	Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research (GlobeNewswire)
Feb-27-23 06:50AM	Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023 (GlobeNewswire) -10.54%
Feb-17-23 06:50AM	Bright Minds Biosciences Announces Non-Executive Director Appointment (GlobeNewswire)
Feb-08-23 04:05PM	Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements (GlobeNewswire) -6.58%
Jan-27-23 04:05PM	Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency (GlobeNewswire) -6.59%
Jan-09-23 04:05PM	Bright Minds Biosciences Announces Resignation of Board Member (GlobeNewswire) -7.46%
Dec-02-22 07:07PM	Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement (GlobeNewswire)
Nov-28-22 06:50AM	Bright Minds Biosciences Announces Non-Brokered Private Placement (GlobeNewswire) +10.78%
Nov-23-22 11:35AM	Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
Sep-07-22 06:50AM	Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors (GlobeNewswire)
Aug-31-22 06:50AM	Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome (GlobeNewswire) -15.42%
Aug-30-22 03:35PM	Bright Minds Biosciences Announces Closing of $4 Million Unit Offering (GlobeNewswire) -23.05%
Aug-23-22 09:07PM	Bright Minds Announces Pricing of Overnight Marketed Offering of Units (GlobeNewswire) -38.43% +48.87%
Aug-22-22 07:05PM	Bright Minds Announces Overnight Marketed Offering of Units (GlobeNewswire) +72.80%
Aug-18-22 03:34PM	Bright Minds Biosciences Comments on Recent Trading Activity (GlobeNewswire) +121.43%
Jun-27-22 06:50AM	Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization (GlobeNewswire)
May-12-22 06:50AM	Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome (GlobeNewswire)
May-02-22 06:50AM	Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties (GlobeNewswire)
Apr-19-22 06:50AM	Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders (GlobeNewswire) +8.40%
Mar-14-22 06:50AM	Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial (GlobeNewswire)
Mar-08-22 07:30AM	Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire)
Jan-04-22 04:05PM	Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference (GlobeNewswire)
Dec-15-21 05:13PM	Canadian Securities Exchange's November 2021 Performance Includes Strong Listings Growth and New Financing Milestone (Newsfile) +5.88%
Dec-06-21 06:50AM	Bright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference (GlobeNewswire)
Nov-30-21 07:30AM	Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases (GlobeNewswire) -8.35%

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in Chicago, IL.

Co-FounderMr. Ian McDonald

C.A.Mr. Ryan E. S. K. Cheung B.Com.

Ph.D.Dr. Jan Torleif Pedersen M.Sc.

COO & Senior Scientific OfficerMr. Alex Vasilkevich

Ph.D.Dr. Emer Leahy M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cormorant Asset Management, LP	Former 10% Owner	Apr 28 '26	Sale	89.50	109,331	9,785,124	950,000	Apr 30 04:07 PM

CRBP Corbus Pharmaceuticals Holdings Inc daily Stock Chart

Peers: OABI CAMP RNA TNXP UNCY KPTI CNTX ELTX TENX ENLV

| Held by: VTI IWM VXF IWN VTWO FESM DFAS IWC DFMC AVSC

Index	RUT
Market Cap	145.64M
Enterprise Value	31.96M
Income	-101.90M
Sales	0.00M
Book/sh	5.48
Cash/sh	6.10
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	36
IPO	Oct 27, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.38
P/C	1.23
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.71
Current Ratio	5.71
Debt/Eq	0.04
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	-6.18
EPS next Y	-5.51
EPS next Q	-1.21
EPS this Y	7.89%
EPS next Y	-1.46%
EPS next 5Y	1.30%
EPS past 3/5Y	16.56% 32.70%
Sales past 3/5Y	- -
EPS Y/Y TTM	-29.66%
Sales Y/Y TTM	-
EPS Q/Q	-25.12%
Sales Q/Q	-
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-43.79% -

Insider Own	10.22%
Insider Trans	-1.21%
Inst Own	62.73%
Inst Trans	4.24%
ROA	-80.85%
ROE	-95.58%
ROIC	-96.59%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-20.26%
SMA50	-20.43%
SMA200	-17.23%
Trades

Shs Outstand	18.67M
Shs Float	17.36M
Short Float	12.94%
Short Ratio	3.20
Short Interest	2.25M
52W High	20.56 -63.38%
52W Low	6.32 19.05%
Volatility	10.98% 8.41%
ATR (14)	0.66
RSI (14)	32.75
Beta	2.58
Rel Volume	0.01
Avg Volume	701.19K
Volume	500

Perf Week	8.82%
Perf Month	-27.46%
Perf Quarter	-10.99%
Perf Half Y	-10.68%
Perf YTD	-7.49%
Perf Year	-34.86%
Perf 3Y	10.74%
Perf 5Y	-77.18%
Perf 10Y	-96.40%
Recom	1.00
Target Price	34.02
Prev Close	7.65
Price	7.53
Change %	-1.57%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-29-26	Initiated	Guggenheim	Buy	$45
Jul-30-25	Resumed	B. Riley Securities	Buy	$28
Feb-28-25	Initiated	William Blair	Outperform
Dec-02-24	Initiated	Piper Sandler	Overweight
Jul-30-24	Initiated	Wedbush	Outperform	$85
Jul-22-24	Resumed	H.C. Wainwright	Buy	$80
Jun-26-24	Initiated	B. Riley Securities	Buy	$85
Jun-03-24	Reiterated	Oppenheimer	Outperform	$60 → $80
May-13-24	Initiated	RBC Capital Mkts	Outperform	$77
Mar-06-24	Upgrade	Jefferies	Hold → Buy	$4 → $46
Sep-08-20	Downgrade	ROTH Capital	Buy → Neutral	$40 → $3
Sep-08-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-08-20	Downgrade	Jefferies	Buy → Hold	$18 → $2.50
Sep-08-20	Downgrade	BTIG Research	Buy → Neutral
Jul-07-20	Initiated	ROTH Capital	Buy	$40
Jun-17-20	Initiated	BTIG Research	Buy	$22
Mar-26-20	Initiated	Nomura	Buy	$12
Apr-05-19	Initiated	Jefferies	Buy
Mar-20-19	Initiated	Oppenheimer	Outperform	$28
Jan-11-19	Reiterated	Cantor Fitzgerald	Overweight	$36 → $38

Show Previous Ratings

Sep-14-26 09:28AM	Corbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial Data (InvestorsHub)
07:00AM	Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity (GlobeNewswire)
Sep-11-26 04:01PM	Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity (GlobeNewswire)
Aug-17-26 10:00AM	Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-26 08:12AM	Corbus Pharmaceuticals: Q2 Earnings Snapshot (Associated Press)
08:00AM	Loading…
08:00AM	Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-04-26 08:30AM	Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity (GlobeNewswire) +5.38%
Jul-28-26 08:00AM	Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer (GlobeNewswire)
Jul-06-26 08:00AM	Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer (GlobeNewswire)
May-26-26 07:00AM	Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers (GlobeNewswire) -30.31%
May-21-26 08:00AM	Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call (GlobeNewswire) +18.29%
May-14-26 08:00AM	Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors (GlobeNewswire)
May-13-26 07:00AM	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.30%
May-12-26 08:06AM	Corbus Pharmaceuticals: Q1 Earnings Snapshot (Associated Press)
08:00AM	Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update (GlobeNewswire)
08:00AM	Loading…
May-05-26 08:00AM	Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026 (GlobeNewswire)
Apr-29-26 09:42AM	Spotify upgraded, Alibaba initiated: Wall Street's top analyst calls (The Fly)
Apr-22-26 08:00AM	Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701 (GlobeNewswire)
Apr-14-26 08:00AM	Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity (GlobeNewswire)
Apr-07-26 08:00AM	Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer (GlobeNewswire)
Mar-18-26 08:00AM	Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit (GlobeNewswire) -6.02%
Mar-09-26 07:48AM	Corbus Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance) +19.23%
07:30AM	Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-26-26 03:08AM	Corbus Pharmaceuticals Touts Catalyst-Rich 2026 With CRB-701 and CRB-913 Data Readouts Ahead (MarketBeat) +6.18%
Feb-12-26 08:00AM	Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference (GlobeNewswire)
Jan-05-26 07:30AM	Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-25 11:16AM	2 Pharma Stocks Pop on Strong Obesity Drug Trial Results (Schaeffer's Research) -5.65%
07:00AM	Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss (GlobeNewswire)
Dec-10-25 04:01PM	Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 (GlobeNewswire)
Nov-12-25 08:09AM	Corbus Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance) +7.39%
08:00AM	Loading…
08:00AM	Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-06-25 08:00AM	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-31-25 02:40AM	Corbus Pharmaceuticals Announces Pricing of Public Offering (GlobeNewswire) -26.09%
Oct-30-25 04:31PM	Corbus Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
Oct-18-25 03:00AM	Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25 (GlobeNewswire)
Oct-14-25 08:00AM	Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025 (GlobeNewswire)
Oct-07-25 08:00AM	Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium (GlobeNewswire)
Sep-22-25 08:00AM	Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025 (GlobeNewswire)
Sep-16-25 08:00AM	FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma (GlobeNewswire) +9.61%
Aug-08-25 10:15AM	Can Cannabis Stocks Reverse Their Prolonged Downtrend? (Zacks) -6.33%
Aug-05-25 08:11AM	Corbus Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-30-25 08:00AM	Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress (GlobeNewswire)
Jun-30-25 08:00AM	Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity (GlobeNewswire) -6.76%
Jun-25-25 08:00AM	Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab (GlobeNewswire) +8.92%
Jun-24-25 04:05PM	Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium (GlobeNewswire)
May-23-25 11:13AM	3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies (Zacks)
May-22-25 08:00AM	Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-19-25 08:00AM	Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair (GlobeNewswire) +5.72%
May-16-25 07:48AM	Is Small-Cap Corbus Pharma a Worthy Cannabis Investment? (Zacks)
May-08-25 08:00AM	Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +8.48%
07:20AM	Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold? (Zacks)
May-06-25 08:08AM	Corbus Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance) -15.77%
08:00AM	Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-29-25 08:14AM	3 Unconventional Cannabis Stocks to Watch in 2025 (Zacks)
Apr-18-25 09:55AM	Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High? (Zacks)
Mar-28-25 08:00AM	Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity (GlobeNewswire)
Mar-20-25 09:35AM	After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) (Zacks)
Mar-19-25 09:35AM	After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) (Zacks)
Mar-13-25 12:00PM	Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should Know (Zacks) -7.09%
Mar-11-25 08:17AM	Corbus Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-25-25 08:00AM	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-14-25 01:17PM	Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate (Benzinga) -10.23%
07:30AM	CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025 (GlobeNewswire)
Feb-11-25 07:30AM	Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU (GlobeNewswire) -10.22%
Jan-28-25 08:00AM	Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-08-25 08:00AM	Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025 (GlobeNewswire)
Jan-06-25 08:00AM	Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-24 07:00AM	Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors (GlobeNewswire)
Dec-04-24 12:31PM	Why Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Dec-03-24 07:00AM	FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer (GlobeNewswire) -6.11%
Nov-26-24 06:54AM	Corbus Pharmaceuticals Holdings, Inc. (CRBP): An Oversold Healthcare Stock to Invest In Now (Insider Monkey)
Nov-21-24 08:00AM	Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
Nov-12-24 08:00AM	Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-07-24 07:28AM	Corbus Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-04-24 04:10PM	Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat (Investor's Business Daily) +8.22%
07:00AM	Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024 (GlobeNewswire)
Oct-29-24 08:00AM	Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire)
Oct-16-24 08:00AM	Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701) (GlobeNewswire)
Oct-15-24 07:02PM	Millennium Management LLC Adjusts Stake in Corbus Pharmaceuticals (GuruFocus.com)
Oct-11-24 07:02PM	Octagon Capital Advisors LP Increases Stake in Corbus Pharmaceuticals Holdings Inc (GuruFocus.com)
Oct-03-24 05:07AM	Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) the Best Russell 2000 Stock to Buy According to Analysts? (Insider Monkey)
Sep-26-24 08:00AM	Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit (GlobeNewswire)
Sep-24-24 09:41PM	Cormorant Asset Management's Strategic Acquisition in Corbus Pharmaceuticals (GuruFocus.com) +16.41%
Sep-20-24 03:18PM	Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players (Benzinga) -62.26%
Sep-12-24 07:59AM	Transforming Cancer Therapy Stocks to Watch In The Oncology Sector (News Direct)
Sep-05-24 08:00AM	Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference (GlobeNewswire) -8.32%
Sep-04-24 07:29PM	Corbus Pharmaceuticals Holdings, Inc. (CRBP): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-27-24 08:03PM	Corbus Pharmaceuticals Holdings, Inc. (CRBP): One of Oppenheimers Top Stock Picks For the Next 12 Months (Insider Monkey)
Aug-26-24 09:55AM	Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet (Zacks)
Aug-21-24 05:00AM	The Future of Medicine: Key Biotech Stocks to Watch (News Direct) +7.45%
Aug-20-24 08:00AM	Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung (GlobeNewswire)
Aug-09-24 12:00PM	Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why (Zacks) +5.54%
09:55AM	Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to Trade (Zacks)
Aug-06-24 08:08AM	Corbus Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-30-24 08:50AM	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August (GlobeNewswire) +7.13%

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

CEO & DirectorDr. Yuval Cohen Ph.D.

M.B.A.Mr. Sean F. Moran CPA

Ph.D.Dr. Ian Hodgson B.Sc.

M.S.Mr. G. Scott Goeken J.D.

Vice President of Human ResourcesMs. Christina Bertsch M.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ben Yong	Director	Sep 14 '26	Sale	7.84	2,000	15,683	9,383	Sep 15 04:59 PM
Saxena Nishant C	Chief Business Officer	Aug 11 '26	Buy	9.63	2,600	25,036	77,900	Aug 12 04:30 PM
Cohen Yuval	Chief Executive Officer	Aug 07 '26	Sale	10.08	17,000	171,396	157,316	Aug 10 04:30 PM
Moran Sean F.	Chief Financial Officer	Aug 07 '26	Sale	10.08	12,000	120,971	84,694	Aug 10 04:30 PM
Stifel, Nicolaus & Company, In	Officer	Aug 07 '26	Proposed Sale	10.08	12,000	120,971		Aug 07 04:23 PM
Stifel, Nicolaus & Company, In	Officer	Aug 07 '26	Proposed Sale	10.08	17,000	171,396		Aug 07 04:04 PM
Smethurst Dominic	Officer	Jul 27 '26	Proposed Sale	9.20	23,025	211,818		Jul 27 04:06 PM
Kung Winston	Director	Jun 10 '26	Sale	7.91	2,026	16,033	12,140	Jun 11 04:30 PM
Altmeyer Anne	Director	Jun 10 '26	Sale	7.91	2,412	19,088	7,579	Jun 11 04:30 PM
Jenkins John Kenneth	Director	Jun 10 '26	Sale	7.91	4,800	37,986	3,833	Jun 11 04:30 PM
Saxena Nishant C	Chief Business Officer	Jun 03 '26	Buy	7.58	9,000	68,220	75,300	Jun 03 05:36 PM
Saxena Nishant C	Chief Business Officer	Jun 02 '26	Buy	7.33	4,500	32,998	66,300	Jun 03 05:36 PM
Smethurst Dominic	Chief Medical Officer	Mar 02 '26	Sale	8.30	6,097	50,601	89,790	Mar 04 04:30 PM
Smethurst Dominic	Officer	Mar 02 '26	Proposed Sale	8.30	6,097	50,601		Mar 02 04:08 PM
Hodgson Ian	Chief Operating Officer	Feb 17 '26	Sale	7.38	847	6,253	51,080	Feb 18 04:32 PM
Moran Sean F.	Chief Financial Officer	Feb 13 '26	Sale	7.78	4,701	36,588	96,694	Feb 18 04:31 PM
Cohen Yuval	Chief Executive Officer	Feb 13 '26	Sale	7.78	13,871	107,952	174,316	Feb 18 04:30 PM
Cohen Yuval	Officer	Feb 13 '26	Proposed Sale	40.63	20,000	812,600		Feb 13 04:02 PM
Smethurst Dominic	Chief Medical Officer	Feb 03 '26	Sale	8.09	3,285	26,575	95,887	Feb 04 04:25 PM
Hodgson Ian	Chief Operating Officer	Feb 03 '26	Sale	8.09	2,415	19,537	51,927	Feb 04 04:24 PM
Cormorant Asset Management, LP	10% Owner	Dec 11 '25	Sale	11.46	30,029	344,012	2,344,971	Dec 15 04:18 PM
Cohen Yuval	Chief Executive Officer	Oct 24 '25	Option Exercise	4.26	18,660	79,492	156,847	Oct 27 04:23 PM
Cohen Yuval	Chief Executive Officer	Oct 27 '25	Option Exercise	4.26	8,973	38,225	147,160	Oct 27 04:23 PM
Cohen Yuval	Chief Executive Officer	Oct 24 '25	Sale	17.01	18,660	317,407	138,187	Oct 27 04:23 PM
Cohen Yuval	Chief Executive Officer	Oct 27 '25	Sale	17.14	8,973	153,797	138,187	Oct 27 04:23 PM
Moran Sean F.	Chief Financial Officer	Oct 24 '25	Option Exercise	4.26	12,981	55,299	86,294	Oct 27 04:22 PM
Moran Sean F.	Chief Financial Officer	Oct 24 '25	Sale	17.02	12,981	220,937	73,313	Oct 27 04:22 PM
Cohen Yuval	Officer	Oct 24 '25	Proposed Sale	17.01	27,633	469,977		Oct 24 04:18 PM
Moran Sean F.	Officer	Oct 24 '25	Proposed Sale	17.02	12,981	220,922		Oct 24 04:14 PM
Altmeyer Anne	Director	Oct 20 '25	Option Exercise	4.80	1,060	5,088	7,251	Oct 21 04:54 PM
Altmeyer Anne	Director	Oct 20 '25	Sale	20.50	1,060	21,730	6,191	Oct 21 04:54 PM

Open in Screener

EYPT

EyePoint Inc

4.06

Sep 22 • 4:04 AM ET +0.04 (1.00%)

Healthcare Biotechnology USA Small NASD

Peers: OCS GKOS BMRN KRYS RYTM VKTX INCY AXSM MDGL NBIX

| Held by: VTI IWM XPH VXF IWO VTWO SCHA IHE VHT DFAS

Index	RUT
Market Cap	350.02M
Enterprise Value	191.92M
Income	-306.64M
Sales	2.79M
Book/sh	1.96
Cash/sh	2.09
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	214
IPO	Jan 27, 2005

P/E	-
Forward P/E	-
PEG	-
P/S	125.45
P/B	2.07
P/C	1.94
P/FCF	-
EV/EBITDA	-
EV/Sales	68.79
Quick Ratio	4.46
Current Ratio	4.50
Debt/Eq	0.13
LT Debt/Eq	0.12
Option/Short	Yes / Yes

EPS (ttm)	-3.74
EPS next Y	-2.73
EPS next Q	-0.91
EPS this Y	-17.31%
EPS next Y	26.66%
EPS next 5Y	19.87%
EPS past 3/5Y	-4.94% 2.18%
Sales past 3/5Y	-8.83% -1.85%
EPS Y/Y TTM	-39.78%
Sales Y/Y TTM	-94.63%
EPS Q/Q	-28.45%
Sales Q/Q	-90.49%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-8.00% 12.37%

Insider Own	6.38%
Insider Trans	0.06%
Inst Own	109.60%
Inst Trans	8.49%
ROA	-115.86%
ROE	-148.70%
ROIC	-164.66%
Gross Margin	-18.29%
Oper. Margin	-11365.22%
Profit Margin	-10994.73%
SMA20	-6.43%
SMA50	-52.60%
SMA200	-68.94%
Trades

Shs Outstand	84.98M
Shs Float	80.71M
Short Float	22.44%
Short Ratio	4.85
Short Interest	18.11M
52W High	19.11 -78.75%
52W Low	3.41 18.89%
Volatility	11.41% 8.15%
ATR (14)	0.55
RSI (14)	33.63
Beta	1.65
Rel Volume	0.00
Avg Volume	3.73M
Volume	61

Perf Week	10.93%
Perf Month	-23.68%
Perf Quarter	-71.77%
Perf Half Y	-68.36%
Perf YTD	-77.78%
Perf Year	-69.61%
Perf 3Y	-51.95%
Perf 5Y	-62.68%
Perf 10Y	-87.62%
Recom	1.92
Target Price	25.55
Prev Close	4.02
Price	4.06
Change %	1.00%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-02-26	Downgrade	TD Cowen	Buy → Hold	$4
Aug-18-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$5
Aug-18-26	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-18-26	Downgrade	Chardan Capital Markets	Buy → Neutral	$5
Aug-17-26	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jul-16-26	Initiated	Stifel	Buy	$40
Jul-08-26	Resumed	Cantor Fitzgerald	Overweight	$47
Jun-17-25	Initiated	RBC Capital Mkts	Outperform	$28
Jan-07-25	Initiated	Citigroup	Buy	$33
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-28-24	Initiated	Jefferies	Buy	$15
Jan-22-24	Initiated	JP Morgan	Overweight	$35
Nov-02-23	Initiated	Mizuho	Buy	$20
Apr-21-23	Initiated	Robert W. Baird	Outperform	$33
Jul-07-22	Initiated	Chardan Capital Markets	Buy	$21
Mar-01-21	Initiated	Cowen	Outperform	$25
Jan-28-21	Initiated	Cantor Fitzgerald	Overweight	$22
Apr-06-20	Downgrade	B. Riley FBR	Buy → Neutral	$4 → $1
Nov-04-19	Resumed	Laidlaw	Buy	$5
Sep-12-19	Initiated	Guggenheim	Buy

Show Previous Ratings

Sep-21-26 05:06PM	These beaten-down stocks could bounce back in January, if history is any guide (MarketWatch)
Sep-16-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.74%
Sep-06-26 06:30AM	Street Calls of the Week (Investing.com)
Sep-02-26 09:54AM	Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls (The Fly)
07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting (GlobeNewswire)
08:39AM	Loading…
Aug-24-26 08:39AM	Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial (Barrons.com) -8.46%
Aug-18-26 10:40AM	EyePoints Duravyu falls short to Eylea in Phase III trial (Clinical Trials Arena) +12.32%
09:37AM	Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls (The Fly)
07:57AM	EyePoints Regulatory Overhang May Take Time To Clear After Wet AMD Trial Setback, RBC Says Retail Calls EYPT Slump A Huge Overreaction (Stocktwits)
Aug-17-26 11:00PM	Why Did EYPT, STLA, ENVX Stocks Plunge To 52-Week Lows Today? (Stocktwits) -66.98%
07:51PM	OCUL, FDMT Stock Clock Best Day In Weeks After EyePoints Trial Setback Heres Why (Stocktwits)
11:14AM	EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction. (Barrons.com)
10:56AM	EyePoint DURAVYU Phase 3 LUGANO Trial Misses Primary Endpoint as Secondary Data Show Reduced Treatment Burden (InvestorsHub)
09:41AM	The Surprising Reason EyePoint Just Crashed 69% (Investor's Business Daily)
09:19AM	EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback Retail Sees Ocular Therapeutics As A Better Buyout Candidate (Stocktwits)
07:00AM	Loading…
07:00AM	EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU 2.7mg in Wet AMD (GlobeNewswire)
Aug-14-26 04:32PM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +9.42%
Aug-05-26 07:33AM	EyePoint: Q2 Earnings Snapshot (Associated Press)
07:00AM	EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Jul-30-26 07:00AM	EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU for Treatment of Diabetic Macular Edema (DME) (GlobeNewswire) +7.89%
Jul-16-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.85%
Jul-13-26 07:00AM	EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer (GlobeNewswire)
Jun-16-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +6.62%
May-19-26 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
May-18-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.26%
May-14-26 07:00AM	EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU, Building Confidence Ahead of Mid-2026 Topline Data (GlobeNewswire)
May-07-26 08:30AM	EyePoint Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary (Moby)
May-06-26 07:21AM	EyePoint: Q1 Earnings Snapshot (Associated Press)
07:00AM	EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Apr-29-26 07:00AM	EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 (GlobeNewswire)
04:01PM	Loading…
Apr-16-26 04:01PM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-20-26 06:12PM	EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug (Reuters)
Mar-16-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-26 04:03PM	EyePoint Inc (EYPT) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising ... (GuruFocus.com) -12.44%
12:36PM	EyePoint Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby)
10:36AM	Eyepoint Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
08:20AM	EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:23AM	EyePoint: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Mar-02-26 07:00AM	EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU for the Treatment of Diabetic Macular Edema (GlobeNewswire)
Feb-26-26 12:15PM	Novavax (NVAX) Beats Q4 Earnings and Revenue Estimates (Zacks)
Feb-25-26 07:00AM	EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026 (GlobeNewswire)
Feb-24-26 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Feb-18-26 07:58AM	EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains? (Zacks)
07:00AM	EyePoint Appoints Michael Campbell as Chief Commercial Officer (GlobeNewswire)
Feb-17-26 08:30AM	Ocular Therapeutix stock news: Why positive data led to a 25% drop (Investing.com) +15.22%
07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-16-26 09:40AM	Wall Street Thinks These 4 Biotech Stocks Will DoubleAt LeastThis Year (24/7 Wall St.)
Feb-13-26 05:12PM	EyePoint Pharmaceuticals Teases Mid-2026 DURAVYU Wet AMD Data, Starts Phase III DME Program (MarketBeat) +15.22%
Feb-05-26 07:00AM	EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-16-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-07-26 07:00AM	EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 (GlobeNewswire)
Dec-22-25 12:00PM	EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know (Zacks) +8.15%
08:10AM	3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 (Zacks)
Dec-20-25 12:00PM	The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside (Barchart)
Dec-17-25 07:00AM	EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-19-25 07:00AM	EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration (GlobeNewswire)
Nov-17-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +13.43%
Nov-07-25 04:00AM	EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-05-25 08:15AM	EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -11.10%
07:22AM	EyePoint Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Nov-04-25 08:06AM	EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-03-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Oct-29-25 07:00AM	EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire)
Oct-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-14-25 10:43PM	EyePoint Announces Pricing of Public Offering (GlobeNewswire) -10.87%
04:35PM	EyePoint Announces Proposed Public Offering of Common Stock (GlobeNewswire)
04:01PM	EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU in Diabetic Macular Edema (GlobeNewswire)
Sep-25-25 09:29AM	Nurix Therapeutics (NRIX) Soars 5.6%: Is Further Upside Left in the Stock? (Zacks) -6.32%
Sep-23-25 01:13PM	Biotech Stocks Rally. 3 Favorite Plays From the Charts. (Barrons.com)
Sep-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-26-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Aug-18-25 04:01PM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-25 08:30AM	EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:30AM	EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (GlobeNewswire)
07:26AM	EyePoint Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Aug-05-25 10:08AM	EyePoint Pharmaceuticals Inc (EYPT) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com) +8.25%
Jul-30-25 06:00PM	Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:00AM	EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
05:57AM	Enrolment concludes in EyePoints Phase III programme of Duravyu for wet AMD (Clinical Trials Arena)
Jul-29-25 07:00AM	EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration (GlobeNewswire)
Jul-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 11:54AM	Breakout Momentum Plays You May Not Know About (MarketBeat) +8.36%
May-28-25 04:01PM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire) +18.12%
May-27-25 07:00AM	EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
May-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +7.17%
May-13-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
May-07-25 02:49PM	Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum (Seeking Alpha)
02:49PM	EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:25AM	EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:22AM	EyePoint Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Apr-30-25 07:00AM	EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire)
Apr-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-25 07:00AM	EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference (GlobeNewswire)

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

PresidentDr. Jay S. Duker M.D.

Executive VP & CFOMr. George O. Elston CPA

Ph.D.Dr. Ramiro Ribeiro M.D.

Chief Scientific OfficerDr. Marcia Sellos-Moura Ph.D.

Chief Legal Officer & Company SecretaryMr. Ron I. Honig Esq.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zaderej Karen L.	Director	Aug 18 '26	Buy	4.93	10,600	52,258	49,100	Aug 18 04:08 PM
Lurker Nancy	Officer	Jul 21 '26	Proposed Sale	13.05	421,235	5,497,117		Jul 21 04:44 PM
Duker Jay S.	President and CEO	Jul 10 '26	Option Exercise	0.00	16,667	0	17,653	Jul 14 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Jun 30 '26	Option Exercise	8.26	4,875	40,268	4,875	Jul 02 04:03 PM
Ribeiro Ramiro	Chief Medical Officer	Jun 30 '26	Sale	15.01	4,875	73,167	0	Jul 02 04:03 PM
Elston George	Chief Financial Officer	May 25 '26	Option Exercise	0.00	7,500	0	95,318	May 27 04:05 PM
Ribeiro Ramiro	Chief Medical Officer	Apr 17 '26	Option Exercise	8.26	2,437	20,130	2,437	Apr 20 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Apr 17 '26	Sale	15.00	2,437	36,555	0	Apr 20 04:07 PM
Ramiro Ribeiro	Officer	Apr 17 '26	Proposed Sale	14.81	9,750	144,398		Apr 17 04:36 PM
Duker Jay S.	President and CEO	Mar 16 '26	Buy	13.15	1,500	19,724	100,665	Mar 16 04:12 PM
Ribeiro Ramiro	Chief Medical Officer	Mar 04 '26	Option Exercise	8.26	2,438	20,138	2,438	Mar 05 04:02 PM
Ribeiro Ramiro	Chief Medical Officer	Mar 04 '26	Sale	17.87	2,438	43,572	0	Mar 05 04:02 PM
Ribeiro Ramiro	Chief Medical Officer	Feb 17 '26	Option Exercise	8.26	2,437	20,130	2,437	Feb 18 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Feb 17 '26	Sale	15.00	2,437	36,555	0	Feb 18 04:07 PM
Lurker Nancy	Director	Jan 06 '26	Option Exercise	0.00	75,133	0	294,346	Jan 07 04:13 PM
Duker Jay S.	President and CEO	Jan 06 '26	Option Exercise	0.00	20,793	0	87,806	Jan 07 04:12 PM
Elston George	Chief Financial Officer	Jan 06 '26	Option Exercise	0.00	15,285	0	96,339	Jan 07 04:12 PM
Ribeiro Ramiro	Chief Medical Officer	Jan 05 '26	Option Exercise	8.26	29,250	241,605	42,544	Jan 07 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Jan 05 '26	Sale	17.10	42,544	727,319	0	Jan 07 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Jan 03 '26	Option Exercise	0.00	19,667	0	19,667	Jan 06 04:47 PM
Duker Jay S.	President and CEO	Jan 05 '26	Option Exercise	0.00	30,000	0	81,518	Jan 06 04:10 PM
Duker Jay S.	President and CEO	Jan 03 '26	Option Exercise	0.00	65,000	0	74,965	Jan 06 04:10 PM
Elston George	Chief Financial Officer	Jan 05 '26	Option Exercise	0.00	15,000	0	85,457	Jan 06 04:10 PM
Elston George	Chief Financial Officer	Jan 03 '26	Option Exercise	0.00	19,667	0	76,781	Jan 06 04:10 PM
Lurker Nancy	Director	Jan 05 '26	Option Exercise	0.00	12,666	0	219,213	Jan 06 04:07 PM
Ramiro Ribeiro	Officer	Jan 05 '26	Proposed Sale	17.48	53,792	940,284		Jan 05 04:42 PM
Cormorant Asset Management, LP	Former 10% Owner	Dec 04 '25	Sale	15.70	60,000	942,240	8,265,000	Dec 08 04:03 PM
Lurker Nancy	Director	Dec 04 '25	Sale	15.11	9,300	140,477	206,547	Dec 05 04:06 PM
Lurker Nancy	Officer	Dec 04 '25	Proposed Sale	15.11	9,300	140,477		Dec 04 10:24 AM
Lurker Nancy	Director	Nov 28 '25	Sale	14.95	500	7,475	215,847	Dec 01 04:09 PM
Lurker Nancy	Director	Nov 26 '25	Sale	14.95	200	2,990	216,347	Dec 01 04:09 PM
Lurker Nancy	Officer	Nov 28 '25	Proposed Sale	14.95	500	7,475		Nov 28 01:23 PM
Lurker Nancy	Officer	Nov 26 '25	Proposed Sale	14.95	200	2,990		Nov 26 04:09 PM
Ribeiro Ramiro	Chief Medical Officer	Nov 11 '25	Sale	11.61	2,722	31,602	0	Nov 12 04:03 PM
Ramiro Ribeiro	Officer	Nov 11 '25	Proposed Sale	11.35	2,722	30,895		Nov 12 06:55 AM

OKUR OnKure Therapeutics Inc daily Stock Chart

Peers: ANTX BDTX TNYA MOLN HURA MENS MSLE ORMP PLX SPRB

| Held by: VTI IWM VXF IWN VTWO IWC TMED BUSM DFAS AVSC

Index	RUT
Market Cap	123.92M
Enterprise Value	-51.54M
Income	-58.70M
Sales	0.00M
Book/sh	4.25
Cash/sh	4.36
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	45
IPO	Apr 09, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.72
P/C	0.70
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	26.75
Current Ratio	26.75
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-3.50
EPS next Y	-1.53
EPS next Q	-0.41
EPS this Y	58.41%
EPS next Y	16.58%
EPS next 5Y	32.97%
EPS past 3/5Y	40.79% 11.29%
Sales past 3/5Y	- -
EPS Y/Y TTM	34.92%
Sales Y/Y TTM	-
EPS Q/Q	72.99%
Sales Q/Q	-
Earnings	Aug 04 AMC
EPS/Sales Surpr.	42.06% -100.00%

Insider Own	31.26%
Insider Trans	-0.01%
Inst Own	65.58%
Inst Trans	13.07%
ROA	-44.24%
ROE	-46.91%
ROIC	-33.99%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-9.95%
SMA50	-19.61%
SMA200	-16.84%
Trades

Shs Outstand	40.50M
Shs Float	27.84M
Short Float	4.75%
Short Ratio	5.91
Short Interest	1.32M
52W High	5.38 -43.12%
52W Low	2.23 37.22%
Volatility	6.15% 7.39%
ATR (14)	0.25
RSI (14)	30.64
Beta	0.09
Rel Volume	0.00
Avg Volume	223.73K
Volume	0

Perf Week	2.00%
Perf Month	-22.14%
Perf Quarter	-31.08%
Perf Half Y	-26.97%
Perf YTD	5.52%
Perf Year	19.07%
Perf 3Y	-95.68%
Perf 5Y	-96.08%
Perf 10Y	-
Recom	1.40
Target Price	15.50
Prev Close	3.06
Price	3.06
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-30-25	Initiated	Evercore ISI	Outperform
Dec-05-24	Initiated	Leerink Partners	Outperform	$33
Oct-10-24	Initiated	Oppenheimer	Outperform	$35
Dec-15-23	Downgrade	Leerink Partners	Outperform → Market Perform
Dec-15-23	Downgrade	Jefferies	Buy → Hold
Dec-15-23	Downgrade	H.C. Wainwright	Buy → Neutral	$30 → $1.50
Dec-14-23	Downgrade	William Blair	Outperform → Mkt Perform
Dec-14-23	Downgrade	Robert W. Baird	Outperform → Neutral	$28 → $3
Dec-14-23	Downgrade	Piper Sandler	Overweight → Neutral	$25 → $4
Dec-14-23	Downgrade	Ladenburg Thalmann	Buy → Neutral
Dec-14-23	Downgrade	BofA Securities	Buy → Underperform	$23 → $1.45
Nov-15-23	Initiated	William Blair	Outperform	$35.55
Aug-28-23	Initiated	H.C. Wainwright	Buy	$30
Jul-03-23	Initiated	BofA Securities	Buy
Sep-19-22	Resumed	H.C. Wainwright	Buy	$31
Jan-27-22	Initiated	Robert W. Baird	Outperform	$28
Dec-21-21	Initiated	H.C. Wainwright	Buy	$28
Nov-22-21	Initiated	Ladenburg Thalmann	Buy	$45
May-04-21	Initiated	SVB Leerink	Outperform	$25
May-04-21	Initiated	Piper Sandler	Overweight	$45

Show Previous Ratings

Aug-31-26 08:00AM	OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-04-26 04:05PM	OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights (GlobeNewswire)
Jul-02-26 08:00AM	OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Ka Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026 (GlobeNewswire)
May-05-26 04:05PM	OnKure Therapeutics Reports First Quarter 2026 Financial Results (GlobeNewswire) -9.96%
Mar-27-26 08:00AM	OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Ka Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies (GlobeNewswire) -13.07%
04:05PM	Loading…
Mar-12-26 04:05PM	OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire) +7.39%
Nov-06-25 04:03PM	OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire) +5.33% -6.96%
Nov-04-25 04:05PM	OnKure Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.20%
Aug-12-25 04:05PM	OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire) +20.00%
May-06-25 07:30AM	OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) -11.16%
Mar-10-25 04:05PM	OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-04-25 08:00AM	OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences (GlobeNewswire) +7.45%
Dec-10-24 07:00AM	OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 (GlobeNewswire) -8.47%
Nov-25-24 05:31PM	OnKure Announces New Date for Upcoming Investor Call (GlobeNewswire)
Nov-05-24 04:05PM	OnKure to Present at the Stifel 2024 Healthcare Conference (GlobeNewswire) +7.90%
05:30PM	Loading…
Nov-01-24 05:30PM	OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire) -6.91%
Oct-07-24 04:32AM	OnKure and Reneo Pharmaceuticals complete merger (Pharmaceutical Technology)
Oct-04-24 04:57PM	OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million (GlobeNewswire) +5.20%
Oct-02-24 08:20PM	Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure (GlobeNewswire)
Aug-13-24 07:35AM	Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results (GlobeNewswire)
May-16-24 10:01AM	Reneo Pharmaceuticals Insider Bought Shares Worth $639,578, According to a Recent SEC Filing (MT Newswires)
May-13-24 08:25AM	Reneo Pharmaceuticals to Merge With OnKure in All-Stock Deal -- Reneo Shares Rise (MT Newswires) -12.15%
07:35AM	Reneo Pharmaceuticals and OnKure Announce Proposed Merger (GlobeNewswire)
May-07-24 01:53PM	RPHM Stock Earnings: Reneo Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
07:35AM	Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results (GlobeNewswire)
Mar-28-24 12:53PM	RPHM Stock Earnings: Reneo Pharmaceuticals Misses EPS for Q4 2023 (InvestorPlace)
07:35AM	Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update (GlobeNewswire)
Mar-25-24 07:00AM	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors (GlobeNewswire)
Dec-21-23 04:13PM	These Stocks under $10 Are Poised To Explode (Insider Monkey)
Dec-15-23 10:19AM	Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study (Zacks) +5.97%
12:35PM	Loading…
Dec-14-23 12:35PM	Why Is Genetic Disease Focused Reneo Pharmaceuticals Stock Plummeting Today? (Benzinga) -82.71%
09:05AM	Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM) (GlobeNewswire)
Nov-13-23 05:04PM	Reneo Pharmaceuticals Inc (RPHM) Reports Q3 2023 Financial Results (GuruFocus.com)
07:35AM	Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-02-23 07:50AM	Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-25-23 07:50AM	Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings (GlobeNewswire)
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey) -5.76%
Oct-09-23 07:50AM	Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM) (GlobeNewswire)
Oct-06-23 08:30AM	Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit (GlobeNewswire) +11.47%
Aug-29-23 07:35AM	Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.30%
Aug-10-23 07:35AM	Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results (GlobeNewswire)
07:31AM	Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) stock price dropped 10% last week; private equity firms would not be happy (Simply Wall St.)
Jul-27-23 11:19AM	Bank of America Says These 2 Stocks Could Double Your Money Heres Why They Could Rally (TipRanks) +17.59%
Jun-30-23 08:25AM	Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum (GlobeNewswire)
Jun-26-23 08:25AM	Reneo Pharmaceuticals Added to Russell 2000® and Russell 3000® Indices (GlobeNewswire)
Jun-15-23 12:44PM	Reneo Pharmaceuticals Announces Presentation and Posters at Mitochondrial Medicine Symposium 2023 (GlobeNewswire)
May-31-23 10:38AM	Update -- Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference (GlobeNewswire)
08:00AM	Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference (GlobeNewswire)
May-21-23 07:42PM	Insiders Pour $1 Million Each Into These 2 Strong Buy Stocks Heres Why Wall Street Thinks They Could Double (or More) (TipRanks)
May-12-23 06:00PM	MP Materials, Pitney Bowes See Activist Investor Action (Barrons.com)
May-11-23 07:45AM	Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results (GlobeNewswire) +6.02%
May-03-23 11:36PM	Reneo Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:01PM	Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Mar-27-23 07:30AM	Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-14-23 07:30AM	Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies (GlobeNewswire)
Mar-09-23 08:00AM	Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023 (GlobeNewswire)
Mar-03-23 06:07AM	Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) largest shareholders are private equity firms who were rewarded as market cap surged US$33m last week (Simply Wall St.)
Feb-02-23 07:35AM	Reneo Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-31-23 07:35AM	Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD) (GlobeNewswire)
Dec-04-22 07:12AM	Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Nov-08-22 07:35AM	Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-03-22 08:00AM	Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire)
Sep-14-22 06:02AM	Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) biggest owners are private equity firms who got richer after stock soared 25% last week (Simply Wall St.) +8.24%
Sep-06-22 08:35AM	Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-29-22 07:35AM	Reneo Pharmaceuticals Announces Poster Presentations at the International Network for Fatty Acid Oxidation Research and Management Annual Meeting (GlobeNewswire)
Aug-09-22 08:00AM	Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results (GlobeNewswire) -5.26%
Aug-04-22 09:10AM	Insiders who bought in the last 12 months lose an additional US$83k as Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) drops to US$57m (Simply Wall St.) +14.89%
Aug-02-22 07:30AM	Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors (GlobeNewswire) -15.92%
Jul-26-22 09:52AM	Reneo Pharmaceuticals Says Metabolic Disorder Program To Enter Next Stage Of Development (Benzinga)
07:30AM	Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates (GlobeNewswire)
Jul-11-22 08:00AM	Reneo Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.84%
Jun-30-22 08:00AM	Reneo Pharmaceuticals to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022) (GlobeNewswire) +13.73%
Jun-20-22 08:33AM	Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Invest In Growth? (Simply Wall St.)
May-10-22 04:05PM	Reneo Pharmaceuticals Reports First Quarter 2022 Financial Results (GlobeNewswire) +9.09%
Mar-23-22 04:05PM	Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-07-22 08:30AM	Reneo Pharmaceuticals Announces Senior Leadership Promotions (GlobeNewswire)
Feb-02-22 08:00AM	Reneo Pharmaceuticals to Participate in SVB Leerink Virtual Global Healthcare Conference (GlobeNewswire) -8.93%
Jan-24-22 08:00AM	Reneo Pharmaceuticals Announces Changes to its Board of Directors (GlobeNewswire)
Jan-10-22 11:55AM	We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate (Simply Wall St.)
Dec-22-21 11:04AM	3 Strong Buy Stocks Under $10 With Triple-Digit Upside Potential (TipRanks) +15.28%
Nov-11-21 04:05PM	Reneo Pharmaceuticals Reports Third Quarter 2021 Financial Results (GlobeNewswire) +9.08% +5.23%
Nov-01-21 04:05PM	Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire) +6.71%
Oct-14-21 08:00AM	Reneo Pharmaceuticals Announces Notice of Allowance for Patent Application on REN001 (GlobeNewswire)
Oct-11-21 02:35PM	Here's What Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) Shareholder Ownership Structure Looks Like (Simply Wall St.)
08:00AM	Reneo Pharmaceuticals Appoints Ashley Hall as Chief Development Officer (GlobeNewswire)
Sep-28-21 08:26AM	Reneo Pharmaceuticals Hosting Key Opinion Leader Webinar on McArdle Disease and other Genetic Mitochondrial Myopathies (GlobeNewswire)
Sep-09-21 09:12AM	Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.69%
Aug-11-21 05:55AM	Reneo Pharmaceuticals Reports Second Quarter 2021 Financial Results (GlobeNewswire)
Jul-28-21 08:00AM	Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study (GlobeNewswire)
Jul-12-21 09:30AM	We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate (Simply Wall St.) +5.29%
Jul-09-21 08:00AM	Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction (GlobeNewswire)
Jul-07-21 08:00AM	Reneo Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference (GlobeNewswire)
Jun-29-21 08:00AM	Reneo Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices (GlobeNewswire)
May-20-21 06:00AM	Reneo Pharmaceuticals Reports First Quarter 2021 Financial Results (GlobeNewswire) +6.34%
May-19-21 06:00AM	Reneo Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference (GlobeNewswire) +5.62%
Apr-13-21 08:14AM	The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug (Benzinga)
Apr-09-21 12:32PM	Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM Stock IPO Begin Trading Today (InvestorPlace)
Apr-08-21 09:42PM	Reneo Pharmaceuticals Announces Pricing of Initial Public Offering (GlobeNewswire)

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

PresidentDr. Nicholas A. Saccomano Ph.D.

Chief Financial OfficerMr. Jason A. Leverone CPA

M.P.H.Dr. Samuel Agresta M.D.

Chief Scientific OfficerDr. Dylan Hartley Ph.D.

General Counsel & SecretaryMr. Rogan P. Nunn J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Saccomano Nicholas A	President and CEO	Jun 22 '26	Sale	4.40	86	378	11,247	Jun 24 07:29 PM
Leverone Jason A.	Chief Financial Officer	Jun 22 '26	Sale	4.40	303	1,332	18,802	Jun 24 07:27 PM
Saccomano Nicholas A	President and CEO	Mar 23 '26	Sale	4.16	86	357	7,333	Mar 24 06:57 PM
Leverone Jason A.	Chief Financial Officer	Mar 23 '26	Sale	4.16	301	1,251	16,000	Mar 24 06:56 PM
Saccomano Nicholas A	President and CEO	Dec 22 '25	Sale	2.97	87	258	7,419	Dec 23 08:09 PM
Leverone Jason A.	Chief Financial Officer	Dec 22 '25	Sale	2.97	302	896	16,301	Dec 23 08:08 PM

AARD Aardvark Therapeutics Inc daily Stock Chart

Peers: CNTB GALT GNLX IMUX KZIA PYXS VRCA AGEN EDSA SPRO

| Held by: VTI VXF IBB IWC BUSM IBBQ DFMC BIB AVSC

Index	-
Market Cap	121.90M
Enterprise Value	48.71M
Income	-69.89M
Sales	0.00M
Book/sh	3.42
Cash/sh	3.38
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	40
IPO	Feb 13, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.63
P/C	1.65
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	12.63
Current Ratio	12.63
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-3.21
EPS next Y	-2.56
EPS next Q	-0.72
EPS this Y	-7.54%
EPS next Y	18.64%
EPS next 5Y	5.48%
EPS past 3/5Y	-60.85% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-89.45%
Sales Y/Y TTM	-
EPS Q/Q	0.56%
Sales Q/Q	-
Earnings	Aug 11 AMC
EPS/Sales Surpr.	24.52% -

Insider Own	41.42%
Insider Trans	-0.84%
Inst Own	25.27%
Inst Trans	-6.33%
ROA	-61.06%
ROE	-66.02%
ROIC	-93.09%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-3.15%
SMA50	-10.73%
SMA200	-28.11%
Trades

Shs Outstand	21.88M
Shs Float	12.82M
Short Float	3.98%
Short Ratio	2.01
Short Interest	0.51M
52W High	17.94 -68.95%
52W Low	3.35 66.27%
Volatility	8.25% 11.89%
ATR (14)	0.65
RSI (14)	47.55
Beta	3.76
Rel Volume	0.00
Avg Volume	253.27K
Volume	0

Perf Week	0.36%
Perf Month	-5.43%
Perf Quarter	36.52%
Perf Half Y	36.86%
Perf YTD	-57.56%
Perf Year	-48.85%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	2.36
Target Price	10.12
Prev Close	5.57
Price	5.57
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
May-15-26	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$3
Mar-02-26	Downgrade	Stifel	Buy → Hold	$6
Mar-02-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$6
Mar-02-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$7
Mar-02-26	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-28-26	Initiated	B. Riley Securities	Buy	$32
Dec-23-25	Initiated	Oppenheimer	Outperform	$35
Dec-12-25	Initiated	William Blair	Outperform
Dec-03-25	Initiated	Raymond James	Strong Buy	$47
Nov-07-25	Initiated	BTIG Research	Buy	$26
Sep-29-25	Initiated	Stifel	Buy	$24
Jun-30-25	Initiated	H.C. Wainwright	Buy	$40
Mar-10-25	Initiated	RBC Capital Mkts	Outperform	$21
Mar-10-25	Initiated	Morgan Stanley	Overweight	$29
Mar-10-25	Initiated	Cantor Fitzgerald	Overweight	$50
Mar-10-25	Initiated	BofA Securities	Buy	$22

Show Previous Ratings

Sep-17-26 03:25PM	Robbins LLP is Investigating Allegations that Aardvark Therapeutics, Inc. Misled Investors Regarding the Viability and Efficacy of its Lead Drug Candidate ARD-101 (Newsfile) +7.38%
Sep-04-26 05:21PM	AARD Stockholders Have Rights - If You Lost Money Investing in Aardvark Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses (Business Wire) -6.11%
Aug-25-26 09:02AM	Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately (PR Newswire) +5.38%
Aug-24-26 01:01PM	Did You Lose Money Investing in Aardvark Therapeutics, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against AARD (Newsfile)
Aug-17-26 01:31PM	Aardvark Therapeutics Inc (AARD) (Q2 2026) Earnings Call Highlights: Board Re-Elected, Auditor ... (GuruFocus.com)
04:53PM	Loading…
Aug-11-26 04:53PM	Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire) -8.62%
Jul-22-26 04:00PM	Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman (PR Newswire) +6.58%
Jun-25-26 09:00AM	Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS (PR Newswire)
Jun-19-26 09:00AM	Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS (PR Newswire)
May-21-26 09:00AM	Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS (PR Newswire) +5.13%
May-15-26 07:58AM	FDA hold puts Aardvark Prader-Willi drug in limbo (BioPharma Dive) -32.10%
May-14-26 04:01PM	Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold (GlobeNewswire)
May-07-26 08:00AM	Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-10-26 04:17PM	Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman (PR Newswire)
Mar-23-26 04:05PM	Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire) -7.26%
08:54AM	Loading…
Mar-04-26 08:54AM	What's Going On With Aardvark Therapeutics Stock On Wednesday? (Benzinga) +15.10%
Mar-02-26 09:49AM	Why Aardvark Therapeutics Just Lost More Than Half Its Value (Investor's Business Daily) -56.20%
07:02AM	Why Is Aardvark Therapeutics Stock Sinking Monday? (Benzinga)
05:23AM	Stock Market Today: S&P 500, Dow Jones Futures Slide Amid War Against Iran- AMTD Digital, Aardvark, MongoDB In Focus (Benzinga)
03:26AM	Safety concerns spur Aardvark to halt key Prader-Willi drug trial (BioPharma Dive)
Feb-27-26 04:05PM	Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome (GlobeNewswire)
Feb-13-26 08:00AM	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-12-26 08:00AM	Aardvark Therapeutics Announces Leadership Appointments (GlobeNewswire)
08:00AM	Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer (GlobeNewswire)
Feb-10-26 08:00AM	Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome (GlobeNewswire) -6.45%
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly)
Dec-11-25 04:27PM	Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win (Investor's Business Daily) +11.66% -7.56%
Dec-10-25 04:05PM	Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome (GlobeNewswire)
Nov-25-25 04:05PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in December (GlobeNewswire)
Nov-13-25 04:05PM	Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates (GlobeNewswire) -8.66%
04:05PM	Loading…
Nov-11-25 04:05PM	Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +5.94%
Nov-07-25 09:33AM	Datadog, Trade Desk upgraded: Wall Street's top analyst calls (The Fly)
Nov-04-25 12:00PM	Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025 (GlobeNewswire) -5.68%
Nov-03-25 05:55PM	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
08:00AM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in November (GlobeNewswire)
Oct-22-25 08:00AM	Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek (GlobeNewswire) -8.28%
Oct-17-25 09:27AM	Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment (Insider Monkey)
Oct-08-25 08:00AM	Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome (GlobeNewswire)
Sep-23-25 04:05PM	Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum (GlobeNewswire) +6.38%
Sep-22-25 08:01AM	MapLight lines up an IPO in bid to challenge Bristol Myers schizophrenia drug (BioPharma Dive)
Sep-10-25 09:22PM	LB Pharmaceuticals raises $285 million in US IPO (Reuters)
Sep-04-25 08:00AM	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-27-25 04:10PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in September (GlobeNewswire) -5.67% -5.56%
Aug-13-25 04:10PM	Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates (GlobeNewswire) +11.55%
Aug-12-25 08:00AM	Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy (GlobeNewswire) -9.96%
Jul-18-25 08:00AM	Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) (GlobeNewswire)
Jul-15-25 07:30AM	OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company (PR Newswire)
Jul-01-25 05:31PM	Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress (Benzinga)
Jun-24-25 08:00AM	Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference (GlobeNewswire) +18.23%
Jun-03-25 09:55AM	Wall Street Analysts Think Aardvark Therapeutics, Inc. (AARD) Could Surge 180.77%: Read This Before Placing a Bet (Zacks)
May-19-25 04:10PM	Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions (GlobeNewswire) +5.46% +5.47%
May-14-25 04:10PM	Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire) -13.81%
May-07-25 04:05PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in May (GlobeNewswire)
Mar-31-25 04:10PM	Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights (GlobeNewswire) +10.39%
Mar-27-25 04:18PM	Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower (Investor's Business Daily) -5.52% -13.03%
Mar-21-25 09:20AM	Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (SeekingAlpha) +7.95%
Mar-14-25 11:25AM	Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-03-25 02:55PM	Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey)
Feb-12-25 10:38PM	Aardvark Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

CEODr. Tien-Li Lee M.D.

CFO & COOMr. Nelson B. Sun M.B.A.

M.P.H.Dr. Manasi Sinha Jaiman M.D.

Executive Vice President of Medical AffairsDr. Dvorit Samid Ph.D.

Chief Research OfficerDr. Zhenhuan Zheng Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sun Nelson	See Remarks	Sep 11 '26	Sale	5.18	62,000	321,179	35,475	Sep 11 08:14 PM
Sun Nelson	See Remarks	Sep 10 '26	Sale	5.00	14,754	73,779	97,475	Sep 11 08:14 PM
NELSON SUN	Officer	Sep 11 '26	Proposed Sale	5.01	33,911	169,894		Sep 11 04:51 PM
NELSON SUN	Officer	Sep 10 '26	Proposed Sale	4.92	42,843	210,788		Sep 10 05:18 PM
Sun Nelson	Chief Financial Officer	Dec 11 '25	Buy	14.40	3,000	43,200	108,484	Dec 12 08:30 PM
Lee Tien-Li	Chief Executive Officer	Dec 11 '25	Buy	14.48	7,000	101,395	1,551,613	Dec 12 08:30 PM
Lee Tien-Li	Chief Executive Officer	Oct 15 '25	Option Exercise	4.24	1,229	5,211	1,544,613	Oct 16 06:14 PM
Jones Bryan	Chief Operating Officer	Oct 15 '25	Option Exercise	4.24	1,250	5,300	1,250	Oct 16 06:12 PM

Peers: SUPN ALKS PRGO BHC INDV HRMY AMRX LNTH TEVA VTRS

| Held by: VTI IWM XPH VXF IWN VTWO IBB FESM SCHA IHE

Index	RUT
Market Cap	371.43M
Enterprise Value	55.51M
Income	-94.46M
Sales	10.36M
Book/sh	8.19
Cash/sh	6.94
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	62
IPO	Sep 26, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	35.85
P/B	0.99
P/C	1.17
P/FCF	-
EV/EBITDA	-
EV/Sales	5.36
Quick Ratio	17.19
Current Ratio	17.19
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-2.39
EPS next Y	-2.17
EPS next Q	-0.62
EPS this Y	-8.51%
EPS next Y	10.59%
EPS next 5Y	-4.63%
EPS past 3/5Y	-24.49% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-6.76%
Sales Y/Y TTM	168.06%
EPS Q/Q	3.24%
Sales Q/Q	1.62%
Earnings	Aug 05 AMC
EPS/Sales Surpr.	4.50% 63.65%

Insider Own	32.61%
Insider Trans	-0.47%
Inst Own	60.94%
Inst Trans	9.71%
ROA	-26.27%
ROE	-28.21%
ROIC	-25.05%
Gross Margin	97.58%
Oper. Margin	-1026.28%
Profit Margin	-912.25%
SMA20	-10.06%
SMA50	-37.71%
SMA200	-52.12%
Trades

Shs Outstand	45.78M
Shs Float	30.93M
Short Float	8.80%
Short Ratio	3.05
Short Interest	2.72M
52W High	25.95 -68.82%
52W Low	4.88 65.92%
Volatility	6.53% 5.41%
ATR (14)	0.64
RSI (14)	30.30
Beta	0.95
Rel Volume	0.00
Avg Volume	892.55K
Volume	21

Perf Week	-1.07%
Perf Month	-14.63%
Perf Quarter	-63.74%
Perf Half Y	-56.56%
Perf YTD	-38.83%
Perf Year	58.37%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.44
Target Price	35.62
Prev Close	8.09
Price	8.09
Change %	0.03%

Date	Action	Analyst	Rating Change	Price Target Change
May-27-26	Initiated	Roth Capital	Buy	$36
May-13-26	Initiated	BTIG Research	Buy	$40
Mar-27-26	Initiated	Needham	Buy	$50
Feb-25-26	Initiated	Oppenheimer	Outperform	$60
Feb-18-26	Upgrade	Jefferies	Hold → Buy	$62
Jan-27-26	Initiated	Piper Sandler	Overweight	$73
Dec-05-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$12
Oct-22-25	Upgrade	Citigroup	Neutral → Buy	$10
Feb-28-25	Initiated	William Blair	Mkt Perform
Dec-10-24	Downgrade	Morgan Stanley	Overweight → Underweight	$40 → $5
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$42 → $7
Dec-09-24	Downgrade	Citigroup	Buy → Neutral	$45 → $7
Oct-21-24	Initiated	Morgan Stanley	Overweight	$40
Oct-21-24	Initiated	Jefferies	Buy	$42
Oct-21-24	Initiated	Citigroup	Buy	$45

Show Previous Ratings

Sep-08-26 08:00AM	BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema (GlobeNewswire)
Sep-02-26 08:00AM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-31-26 11:56AM	Number of shares and votes in BioArctic AB (publ) as of August 31, 2026 (PR Newswire)
Aug-05-26 04:50PM	BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-31-26 05:56PM	BIOA, GLUE Stocks Clock Worst Day In Years Whats The NVO Connection? (Stocktwits) -63.62% +19.25%
11:39AM	Loading…
Jul-14-26 11:39AM	More than 75% of Leqembi-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC 2026 (PR Newswire)
Jun-16-26 08:00AM	BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk (GlobeNewswire)
May-22-26 09:00AM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
May-20-26 09:50AM	Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets (PR Newswire)
May-13-26 09:35AM	AMD, Under Armour downgraded: Wall Street's top analyst calls (The Fly) +5.22%
May-08-26 09:00AM	BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
May-04-26 04:30PM	BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 (GlobeNewswire)
Apr-21-26 07:19AM	BioAge says early data suggest best-in-class potential for inflammation drug (BioPharma Dive)
07:00AM	BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP (GlobeNewswire)
Apr-13-26 04:30PM	BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
08:00PM	Loading…
Apr-07-26 08:00PM	Is Amgen (AMGN) Outperforming Other Medical Stocks This Year? (Quartz)
Mar-24-26 09:00AM	BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 (GlobeNewswire) -13.53%
Feb-26-26 10:07PM	BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion (MarketBeat)
Feb-19-26 04:30PM	BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-29-26 03:00AM	Eli Lilly, BioAge chase NLRP3 inhibitors with pipeline in a pill potential (Pharma Voice)
Jan-21-26 10:30PM	BioAge Announces Pricing of Upsized $115.0 Million Public Offering (GlobeNewswire) -5.63% -6.06%
Jan-20-26 04:01PM	BioAge Announces Proposed Public Offering (GlobeNewswire) +5.75%
09:00AM	BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 (GlobeNewswire)
Jan-12-26 01:06PM	BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio (Investor's Business Daily) +27.23%
09:00AM	BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk (GlobeNewswire)
Dec-13-25 10:35AM	2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole (Motley Fool)
Dec-04-25 09:00AM	BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor (GlobeNewswire) +13.88%
Nov-25-25 04:30PM	BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-07-25 09:00AM	BioAge Labs to Present at Jefferies Global Healthcare Conference in London (GlobeNewswire)
Nov-06-25 04:45PM	BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
07:45AM	Loading…
Nov-05-25 07:45AM	Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy (Motley Fool)
Oct-29-25 06:15AM	Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026? (Motley Fool)
Oct-26-25 06:33PM	BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher? (Motley Fool)
Oct-23-25 07:36AM	Ventyx shares soar after study suggests cardiovascular benefits for experimental drug (BioPharma Dive) +31.40%
Aug-20-25 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-18-25 07:36AM	BioAge commences dosing in trial of obesity treatment candidate BGE-102 (Clinical Trials Arena)
Aug-15-25 09:00AM	BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor (GlobeNewswire)
Aug-06-25 04:30PM	BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-29-25 10:23AM	BioAge (BIOA) to Analyze Over 17,000 Biobank Samples for Drug Discovery (Insider Monkey)
Jun-21-25 06:00PM	BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions (GlobeNewswire)
Jun-17-25 09:00AM	BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank (GlobeNewswire)
Jun-03-25 09:00AM	BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates (GlobeNewswire)
May-30-25 09:05AM	BioAge Labs completes IND-enabling studies for BGE-102 (TipRanks)
May-29-25 11:18PM	BioAge Labs, Inc. (BIOA)'s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 (Insider Monkey)
09:00AM	BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic (GlobeNewswire)
May-27-25 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
May-06-25 04:30PM	BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-21-25 01:02PM	BioAge Labs, Inc. (BIOA): A Bull Case Theory (Insider Monkey)
Mar-22-25 11:00AM	Investors To Focus On PCE Price Index Print As Cintas, Lululemon To Report Earnings (SeekingAlpha)
Mar-20-25 04:30PM	BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024 (GlobeNewswire)
Mar-17-25 01:54PM	BioArctic receives Orphan Drug Designation for exidavnemab the US (PR Newswire)
Mar-04-25 05:07AM	BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman (Newsfile)
Feb-20-25 04:30PM	BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference (GlobeNewswire)
10:36AM	BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman (Newsfile)
Feb-16-25 07:18AM	BIOA COURT NEWS: BioAge Labs has been Sued for Securities Violations; Contact BFA Law by March 10 if You Lost Money (NASDAQ:BIOA) (GlobeNewswire)
Feb-14-25 05:45AM	Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire) +5.97%
Feb-13-25 08:42AM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (Newsfile)
Feb-07-25 05:45AM	BioAge Labs, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-30-25 09:01AM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (Newsfile)
Jan-29-25 05:39AM	BioAge drops obesity drug; Akero, 89bio cash in on MASH data (BioPharma Dive) -6.40%
Jan-28-25 07:27PM	Kessler Topaz Meltzer & Check, LLP Encourages BioAge Labs, Inc. Investors with Losses to Contact the Firm (PR Newswire)
09:00AM	BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs (GlobeNewswire)
Jan-24-25 05:45AM	Shareholders of BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-22-25 03:00AM	After an obesity stumble, BioAge reconnects with its longevity pipeline (Pharma Voice)
Jan-21-25 05:45AM	Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-18-25 03:07AM	BIOAGE LABS (BIOA) Investors are Notified the Company has been Sued and are Urged to Contact BFA Law by March 10 (Newsfile)
Jan-06-25 09:00PM	Bragar Eagel and Squire, P.C. Is Investigating Franklin, MediaAlpha, e.l.f. Beauty, and BioAge and Encourages Investors to Contact the Firm (GlobeNewswire) -7.39%
Jan-03-25 12:51PM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (PR Newswire)
Jan-02-25 09:35AM	BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-01-25 05:00AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile)
Dec-27-24 11:32AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) -6.46%
09:18AM	BioAge Labs, Inc. (BIOA): A Bull Case Theory (Insider Monkey)
Dec-26-24 07:23AM	Kirby McInerney LLP is Investigating Potential Shareholder Claims Against BioAge Labs, Inc. (BIOA) (Newsfile)
Dec-25-24 07:04AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile)
Dec-23-24 10:19AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
Dec-19-24 01:15PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) +20.23%
05:46AM	BioAge and Novartis seek drug targets for ageing-related diseases (Pharmaceutical Technology)
Dec-18-24 09:00AM	BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions (GlobeNewswire)
Dec-16-24 04:20PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
03:00AM	3 closely watched drugs that failed in the clinic (Pharma Voice)
Dec-13-24 10:31AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile) -6.75%
Dec-12-24 06:34PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
Dec-09-24 07:51PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) -76.85%
09:28AM	BioAge halts ongoing Phase II trial of obesity drug due to liver concerns (Clinical Trials Arena)
07:41AM	Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns (Benzinga)
Dec-07-24 06:34AM	BioAge shares tumble after decision to halt obesity drug study (BioPharma Dive)
Dec-06-24 04:35PM	BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity (GlobeNewswire) +9.36% -76.85%
Dec-05-24 04:30PM	BioAge Labs to Present at Goldman Sachs Year-Ahead Catalyst Clinic (GlobeNewswire)
Dec-04-24 04:47PM	Why BioAge Labs (BIOA) is the Best All-Time Low Stock to Buy Right Now? (Insider Monkey)
Nov-21-24 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 11:01PM	BioAge Labs Reports Strong Q3 2024 Achievements (TipRanks) -11.78%
Nov-07-24 04:30PM	BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -10.11% +7.61%
Nov-04-24 09:00AM	BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024 (GlobeNewswire)
Oct-24-24 09:00AM	BioAge Labs to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Oct-21-24 10:53AM	Wall Street analysts initiate coverage of BioAge Labs (Investing.com) +8.26%
Oct-17-24 09:45AM	Prediction: These 2 Stocks Could Soar in 2025 (Motley Fool)
Oct-12-24 02:31PM	Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock (Motley Fool)
Oct-07-24 09:10PM	RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc (GuruFocus.com)
Oct-05-24 07:15AM	3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October (Motley Fool)
Oct-03-24 09:05AM	This IPO Biotech Stock Could Be the Next Eli Lilly (Motley Fool) +5.73%

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Emeryville, CA.

Co-FounderDr. Kristen Fortney Ph.D.

Co-FounderDr. Eric Morgen M.D.

Chief Medical Officer & Executive VP of ResearchDr. Paul D. Rubin M.D.

M.D.Dr. Dov A. Goldstein M.B.A.

Senior Vice President of Finance & AccountingMr. Shane Barton CPA

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Barton Shane	Principal Accounting Officer	Jun 29 '26	Option Exercise	6.61	39,718	262,542	42,350	Jul 01 04:27 PM
Barton Shane	Principal Accounting Officer	Jun 30 '26	Option Exercise	6.53	20,216	132,017	20,216	Jul 01 04:27 PM
Barton Shane	Principal Accounting Officer	Jun 29 '26	Sale	25.21	42,350	1,067,576	0	Jul 01 04:27 PM
Barton Shane	Principal Accounting Officer	Jun 30 '26	Sale	25.19	20,216	509,176	0	Jul 01 04:27 PM
Barton Shane	Officer	Jun 30 '26	Proposed Sale	25.19	20,216	509,177		Jun 30 04:21 PM
Barton Shane	Officer	Jun 29 '26	Proposed Sale	25.21	42,350	1,067,578		Jun 29 04:35 PM
GOLDSTEIN DOV A MD	Chief Financial Officer	Apr 23 '26	Option Exercise	4.38	3,542	15,514	36,575	Apr 24 04:19 PM
RUBIN PAUL D	Chief Medical Officer	Apr 01 '26	Option Exercise	5.05	8,820	44,572	8,820	Apr 03 04:07 PM
RUBIN PAUL D	Chief Medical Officer	Apr 01 '26	Sale	17.81	8,820	157,084	0	Apr 03 04:07 PM
RUBIN PAUL D	Officer	Apr 01 '26	Proposed Sale	17.81	8,820	157,084		Apr 01 10:53 AM
RUBIN PAUL D	Chief Medical Officer	Mar 02 '26	Option Exercise	4.77	7,433	35,470	7,433	Mar 03 04:46 PM
RUBIN PAUL D	Chief Medical Officer	Mar 02 '26	Sale	20.30	7,433	150,890	0	Mar 03 04:46 PM
GOLDSTEIN DOV A MD	Chief Financial Officer	Mar 01 '26	Option Exercise	4.38	3,542	15,514	33,033	Mar 03 04:44 PM
RUBIN PAUL D	Officer	Mar 02 '26	Proposed Sale	20.03	7,433	148,883		Mar 02 10:17 AM
RUBIN PAUL D	Chief Medical Officer	Feb 02 '26	Option Exercise	4.77	7,433	35,470	7,433	Feb 03 04:26 PM
RUBIN PAUL D	Chief Medical Officer	Feb 02 '26	Sale	18.75	7,433	139,369	0	Feb 03 04:26 PM
GOLDSTEIN DOV A MD	Chief Financial Officer	Feb 01 '26	Option Exercise	4.38	3,541	15,510	29,491	Feb 03 04:23 PM
RUBIN PAUL D	Officer	Feb 02 '26	Proposed Sale	18.75	7,433	139,369		Feb 02 09:43 AM
GOLDSTEIN DOV A MD	Chief Financial Officer	Jan 16 '26	Option Exercise	4.38	3,542	15,514	25,950	Jan 21 04:20 PM
GOLDSTEIN DOV A MD	Chief Financial Officer	Jan 13 '26	Option Exercise	8.39	27,000	226,530	49,408	Jan 15 04:22 PM
GOLDSTEIN DOV A MD	Chief Financial Officer	Jan 13 '26	Sale	19.70	27,000	531,828	22,408	Jan 15 04:22 PM
Fortney Kristen	Chief Executive Officer	Jan 13 '26	Sale	18.12	233,107	4,223,036	976,949	Jan 15 04:20 PM
Fortney Kristen	10% Owner	Jan 13 '26	Proposed Sale	18.00	233,107	4,195,926		Jan 13 04:36 PM
GOLDSTEIN DOV A MD	Officer	Jan 13 '26	Proposed Sale	19.70	27,000	531,828		Jan 13 04:16 PM
RUBIN PAUL D	Chief Medical Officer	Jan 02 '26	Option Exercise	4.77	7,433	35,470	7,433	Jan 06 04:24 PM
RUBIN PAUL D	Chief Medical Officer	Jan 02 '26	Sale	12.85	7,433	95,490	0	Jan 06 04:24 PM
RUBIN PAUL D	Officer	Jan 02 '26	Proposed Sale	13.41	7,433	99,677		Jan 02 12:56 PM
RUBIN PAUL D	Chief Medical Officer	Dec 09 '25	Option Exercise	6.57	18,000	118,260	18,000	Dec 11 04:21 PM
RUBIN PAUL D	Chief Medical Officer	Dec 09 '25	Sale	12.00	18,000	216,000	0	Dec 11 04:21 PM
RUBIN PAUL D	Officer	Dec 09 '25	Proposed Sale	12.00	18,000	216,000		Dec 09 11:23 AM
RUBIN PAUL D	Chief Medical Officer	Dec 04 '25	Option Exercise	4.11	68,897	283,167	68,897	Dec 05 06:20 PM
RUBIN PAUL D	Chief Medical Officer	Dec 04 '25	Sale	10.19	68,897	701,909	0	Dec 05 06:20 PM
RUBIN PAUL D	Officer	Dec 04 '25	Proposed Sale	10.19	68,897	701,912		Dec 04 04:30 PM

DRUG

Bright Minds Biosciences Inc

CRBP

Corbus Pharmaceuticals Holdings Inc

EYPT

EyePoint Inc

OKUR

OnKure Therapeutics Inc

AARD

Aardvark Therapeutics Inc

BIOA

BioAge Labs Inc

Upgrade your Finviz experience